Citi Pharma Receives CCP Approval to Acquire 100% Stake in PIP
KARACHI: Citi Pharma Limited has received approval from the Competition Commission of Pakistan (CCP) to acquire 100% of Pakheim International Pharma (Pvt) Limited.
In a notice to the Pakistan Stock Exchange (PSX), Citi Pharma said the CCP issued its approval order on October 9, 2026. The order authorizes the proposed acquisition under Section 31(1)(d)(i) of the Competition Act, 2010. The CCP reviewed the proposed transaction and concluded that it does not raise competition concerns.
Citi Pharma Acquisition Awaits Completion of Formalities
Citi Pharma will proceed with the acquisition under the Share Purchase Agreement signed on May 6, 2026. However, the company must complete all applicable legal, regulatory and other formalities before finalizing the transaction.
The company said it would issue further disclosures, as required, when the transaction reaches the relevant milestones.
The CCP’s approval marks an important regulatory step towards completing Citi Pharma’s acquisition of Pakheim International Pharma.
Citi Pharma Share Price Rises on PSX
Citi Pharma’s share price gained Rs. 0.84 to reach Rs. 62.50 on the PSX at the time of filing this story.
Meanwhile, Pakistan’s listed pharmaceutical sector recorded a 28% year-on-year increase in profitability during fiscal year 2025-26. The sector’s combined profits reached Rs. 42.2 billion, driven mainly by price-led growth and lower finance costs.
Pakheim International Pharma
Pakheim is a rich profile ISO 9001:2008 cGMP compliant company, which is manufacturing of high-quality medicines. It has been ranked among one of the top National Units Regarding Quality Control monitoring facilities and elite standard of medicines.
Pakheim pharmaceutical manufacturing unit is located at 28KM Feroze pur Road Lahore, (Punjab) in area 24 Kanal and the covered area is 55,000sq feet.
Pakheim manufactures a wide range of medicines including tablets, capsules, and dry suspensions, followed by cream, ointments, liquid syrups, and liquid injections, and dry injectable in near future.
Pakheim company includes highly qualified, skilled experienced, and competent professionals who are devoted to the standards of FDA, WHO, and the other international authorities.
About The Author
